Published in J Oncol Pract on September 15, 2015
In Response to "Serum Tumor Marker Use in Patients With Advanced Solid Tumors". J Oncol Pract (2016) 1.06
Clinically Meaningful Use of Blood Tumor Markers in Oncology. Biomed Res Int (2016) 0.79
Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer. J Clin Oncol (2016) 0.77
Reply to F. Dayyani et al. J Oncol Pract (2016) 0.75
Selectin Ligands Sialyl-Lewis a and Sialyl-Lewis x in Gastrointestinal Cancers. Biology (Basel) (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29
American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol (2012) 7.16
Eliminating waste in US health care. JAMA (2012) 5.94
American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol (2013) 4.03
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet (2010) 3.78
Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol (2014) 3.70
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 3.25
Time trend analysis of primary tumor resection for stage IV colorectal cancer: less surgery, improved survival. JAMA Surg (2015) 3.05
Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol (2006) 2.97
Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol (2005) 2.48
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol (2012) 2.38
Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev (2007) 2.27
Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. J Clin Oncol (2009) 1.83
Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer (2011) 1.67
Serum tumor markers. Am Fam Physician (2003) 1.67
Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol (2002) 1.55
Tumor marker usage and medical care costs among older early-stage breast cancer survivors. J Clin Oncol (2014) 1.52
Evaluation of the cost of CA-125 measurement, physical exam, and imaging in the diagnosis of recurrent ovarian cancer. Gynecol Oncol (2013) 1.50
Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev (2000) 1.39
Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg (1998) 1.22
Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. J Clin Oncol (2005) 1.20
Time trends in the treatment and survival of recurrences from colorectal cancer. Ann Oncol (2005) 1.11
Serum CEA and CA 19-9: potential future diagnostic or screening tests for gallbladder cancer? Int J Cancer (1990) 1.05
Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow-up evaluation. A Markov analysis. Cancer (1990) 0.91
Tumor markers in cancer diagnosis and prognosis. CA Cancer J Clin (1988) 0.89
Cost effectiveness of postoperative carcinoembryonic antigen monitoring in colorectal cancer. Cancer (1984) 0.88
Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol (2013) 0.88
A cost-effectiveness approach to the Norwegian follow-up programme in colorectal cancer. Ann Oncol (1997) 0.88
Tamoxifen for disease-negative but MCA-positive breast cancer patients. Oncol Rep (2011) 0.84